受强制性开放获取政策约束的文章 - David M. Goldenberg了解详情
无法在其他位置公开访问的文章：20 篇
Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy
DM Goldenberg, RM Sharkey
Expert opinion on biological therapy 20 (8), 871-885, 2020
强制性开放获取政策： US National Institutes of Health
Combining milatuzumab with bortezomib, doxorubicin, or dexamethasone improves responses in multiple myeloma cell lines
R Stein, MR Smith, S Chen, M Zalath, DM Goldenberg
Clinical Cancer Research 15 (8), 2808-2817, 2009
强制性开放获取政策： US National Institutes of Health
Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects
DM Goldenberg, F Morschhauser, WA Wegener
Leukemia & lymphoma 51 (5), 747-755, 2010
强制性开放获取政策： US National Institutes of Health
Al18F labeling of peptides and proteins
P Laverman, WJ McBride, RM Sharkey, DM Goldenberg, OC Boerman
Journal of Labelled Compounds and Radiopharmaceuticals 57 (4), 219-223, 2014
强制性开放获取政策： US National Institutes of Health
A bispecific antibody-IFNα2b immunocytokine targeting CD20 and HLA-DR is highly toxic to human lymphoma and multiple myeloma cells
EA Rossi, DL Rossi, R Stein, DM Goldenberg, CH Chang
Cancer research 70 (19), 7600-7609, 2010
强制性开放获取政策： US National Institutes of Health
Therapy of advanced B-lymphoma xenografts with a combination of 90Y-anti-CD22 IgG (epratuzumab) and unlabeled anti-CD20 IgG (veltuzumab)
MJ Mattes, RM Sharkey, H Karacay, MS Czuczman, DM Goldenberg
Clinical Cancer Research 14 (19), 6154-6160, 2008
强制性开放获取政策： US National Institutes of Health
Evaluation of anti-human leukocyte antigen-DR monoclonal antibody therapy in spontaneous canine lymphoma
R Stein, C Balkman, S Chen, K Rassnick, M Mcentee, R Page, ...
Leukemia & lymphoma 52 (2), 273-284, 2011
强制性开放获取政策： US National Institutes of Health
Radioactive antibodies: a historical review of selective targeting and treatment of cancer
DM Goldenberg, RM Sharkey
Hospital Practice 38 (3), 82-93, 2010
强制性开放获取政策： US National Institutes of Health
Experience with milatuzumab, an anti-CD74 antibody against immunomodulatory macrophage migration inhibitory factor (MIF) receptor, for systemic lupus erythematosus (SLE)
DJ Wallace, F Figueras, WA Wegener, DM Goldenberg
Annals of the Rheumatic Diseases 80 (7), 954-955, 2021
强制性开放获取政策： US Department of Defense
Advances and challenges in developing cytokine fusion proteins as improved therapeutics
CH Chang, P Gupta, DM Goldenberg
Expert Opinion on Drug Discovery 4 (2), 181-194, 2009
强制性开放获取政策： US National Institutes of Health
Overcoming Dose-Limiting, Radioantibody-lnduced Myelotoxicity
RD Blumenthal, RM Sharkey, DM Goldenberg
Cancer therapy with radiolabeled antibodies, 295-314, 2018
强制性开放获取政策： US National Institutes of Health
The humanized anti-HLA-DR moAb, IMMU-114, depletes APCs and reduces alloreactive T cells: implications for preventing GVHD
X Chen, CH Chang, R Stein, DM Goldenberg
Bone marrow transplantation 47 (7), 967-980, 2012
强制性开放获取政策： US National Institutes of Health
Expression of CD74 by AML blasts and cell lines, and enhanced in vitro cytotoxicity of anti-CD74 antibody after interferon-gamma (IFN-γ) treatment.
JD Burton, R Stein, A Chandra, S Chen, N Mishra, T Shah, ...
Journal of Clinical Oncology 28 (15_suppl), 6576-6576, 2010
强制性开放获取政策： US National Institutes of Health
Use of the monoclonal antibody PAM4 to differentiate pancreatic ductal adenocarcinoma (PDAC) from chronic pancreatitis and benign nonmucinous cysts of the pancreas.
C Shi, DM Goldenberg, DV Gold
Journal of Clinical Oncology 30 (4_suppl), 188-188, 2012
强制性开放获取政策： US National Institutes of Health
Detection of early-stage pancreatic ductal adenocarcinoma (PDAC): Sensitivity, specificity, and discriminatory properties of the serum-based PAM4-immunoassay.
DV Gold, J Gaedcke, BM Ghadimi, M Goggins, RH Hruban, M Liu, ...
Journal of Clinical Oncology 30 (4_suppl), 151-151, 2012
强制性开放获取政策： US National Institutes of Health
Combination of the PAM4 and CA19-9 biomarkers to improve the detection of pancreatic adenocarcinoma.
DV Gold, J Gaedcke, BM Ghadimi, M Goggins, RH Hruban, M Liu, ...
Journal of Clinical Oncology 30 (4_suppl), 164-164, 2012
强制性开放获取政策： US National Institutes of Health
Effect of combination radioimmunotherapy (RAIT) and chemoimmunotherapy on therapeutic response and toxicity in xenograft models of human pancreatic carcinoma: First …
RM Sharkey, H Karacay, SV Govindan, S Moon, A Mostafa, ...
Journal of Clinical Oncology 29 (4_suppl), 206-206, 2011
强制性开放获取政策： US National Institutes of Health
Radioimmunotherapy of Tumors: Pretargeting with Bispecific Antibodies
RM Sharkey, DM Goldenberg
Therapeutic Nuclear Medicine, 607-615, 2012
强制性开放获取政策： US National Institutes of Health
Antibodies for Nuclear Medicine Therapy
DM Goldenberg, RM Sharkey
Therapeutic Nuclear Medicine, 125-138, 2012
强制性开放获取政策： US National Institutes of Health
Radioimmunodetection of Cancer: The Next Dimension
DM Goldenberg, RM Sharkey
Molecular Imaging in Oncology, 571-584, 2008
强制性开放获取政策： US National Institutes of Health
出版信息和资助信息由计算机程序自动确定